Genetic susceptibility to Lewy body disease and the distribution of Lewy pathology

The human brain is a vast, intricate landscape, and when it begins to fail, the signs are often confusing. Two of the most common conditions that cause memory loss and movement problems are Parkinson's disease and dementia with Lewy bodies. For decades, doctors have diagnosed these conditions based on what patients tell them and what they observe: a tremor, a shuffle, a forgotten name. But the brain does not always reveal its secrets through symptoms alone. Under the microscope, both conditions share a specific biological signature: clumps of a protein called alpha-synuclein that gather into structures known as Lewy bodies. These clumps can form in the brainstem, which controls basic functions, or they can spread into the outer layers of the brain, the cortex, which handles thinking and memory. The problem is that clinical diagnoses can be wrong; sometimes a patient thought to have Parkinson's actually has a different disease entirely, and sometimes the spread of these protein clumps does not match the symptoms the patient showed while alive. To truly understand what drives these diseases, scientists need to look past the symptoms and examine the actual biological evidence left behind after death.

A team of researchers set out to map the genetic roots of these diseases by looking directly at the brain tissue of thousands of people. Instead of relying on the clinical labels given to patients while they were alive, they focused on the autopsy reports that confirmed the presence of Lewy bodies. They gathered genetic data from 2,661 individuals whose brains were confirmed to have this specific pathology, along with data from over 12,000 people who did not have the disease. By comparing the DNA of these two groups, they searched for genetic variations that made people more likely to develop the condition. This approach allowed them to bypass the confusion of misdiagnosis and focus on the biological reality of the disease itself.

The study uncovered five distinct genetic locations that significantly increase the risk of developing Lewy body disease. The strongest signal came from a gene called APOE, specifically a variant known as epsilon 4. This gene is already famous for its role in Alzheimer's disease, but here it emerged as the most powerful risk factor for developing Lewy body pathology in general. The researchers also confirmed the importance of genes involved in breaking down proteins, such as GBA1 and TMEM175, and a gene called SNCA, which produces the alpha-synuclein protein itself. A fifth signal was found in a region of the immune system known as the HLA class II, suggesting that the body's immune response plays a role in how these proteins behave. Interestingly, the genetic signal found for the SNCA gene in this study was different from the one usually seen in clinical Parkinson's disease. The researchers found that the variant most strongly linked to the actual presence of Lewy bodies was located at the beginning of the gene, whereas the variant typically associated with Parkinson's symptoms is at the end. This suggests that the genetic factors driving the physical accumulation of the disease might be distinct from those that determine how the disease presents in a living patient.

Perhaps the most revealing discovery was how these genes influence where the disease spreads in the brain. The researchers asked a specific question: what makes the Lewy bodies stay in the lower parts of the brain versus spreading up into the thinking centers? Among all the genetic factors they tested, only the APOE epsilon 4 variant showed a clear link to the spread of the disease. People carrying this variant were significantly more likely to have Lewy bodies in the neocortex, the outer layer of the brain responsible for complex thought, rather than just in the brainstem. This connection held true even when the researchers accounted for the presence of Alzheimer's disease plaques, which often occur alongside Lewy bodies. This finding suggests that the APOE epsilon 4 variant does more than just increase the risk of getting the disease; it appears to influence how far the damage travels. It acts as a driver that pushes the pathology from the deep, primitive parts of the brain out toward the surface, potentially explaining why some patients develop severe dementia while others do not.

The study also clarified what does not seem to matter as much for the spread of the disease. While other genes like GBA1 and SNCA were crucial for determining whether a person would develop Lewy body disease at all, they did not appear to dictate whether the disease would remain localized or spread widely. The researchers found no evidence that these other common risk factors influenced the anatomical distribution of the pathology. This distinction is vital because it separates the genetic causes of getting the disease from the genetic causes of how severe or widespread it becomes. The findings imply that different biological mechanisms are at play: some genes determine if the engine of the disease starts, while the APOE gene seems to determine how far the vehicle travels.

By anchoring their research in the physical reality of the brain rather than the uncertainty of clinical diagnosis, the researchers provided a clearer picture of the genetic architecture of Lewy body disease. They confirmed that the disease shares many genetic roots with clinically diagnosed Parkinson's and dementia, but also highlighted unique features that only become visible when looking at the tissue directly. The work suggests that the immune system, the ability to clear proteins, and lipid metabolism are central to the disease process. Most importantly, it identified a specific genetic factor that governs the extent of the damage, offering a new target for understanding why the disease affects some people's thinking so severely while sparing others. This deeper understanding of the biological landscape could eventually help scientists design treatments that not only stop the disease from starting but also prevent it from spreading to the most critical parts of the brain.